These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17455657)

  • 21. [Heteroresistance in Vancomycin-Intermediate Staphylococcus aureus (VISA), susceptible or resistant?].
    Labarca J
    Rev Chilena Infectol; 2015 Oct; 32(5):497-8. PubMed ID: 26633104
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of Staphylococcus aureus prosthetic valve endocarditis.
    Hassoun A
    Am J Med; 2007 Mar; 120(3):e9; author reply e11. PubMed ID: 17349434
    [No Abstract]   [Full Text] [Related]  

  • 23. The killer bug.
    Shnayerson M
    Fortune; 2002 Sep; 146(6):149-50, 152, 154 passim. PubMed ID: 12360834
    [No Abstract]   [Full Text] [Related]  

  • 24. [Epidemiological investigation of beta-lactam antibiotic induced vancomycin-resistant MRSA from clinical isolated MRSA--comparison of detection rate of BIVR with or without CZX].
    Hososaka Y; Hanaki H; Hayashi I; Kamibeppu K; Sunakawa K
    Kansenshogaku Zasshi; 2004 Aug; 78(8):717-21. PubMed ID: 15478647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experimental study on the efficacy of combinations of glycopeptides and beta-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides.
    Domenech A; Ribes S; Cabellos C; Taberner F; Tubau F; Domínguez MA; Montero A; Liñares J; Ariza J; Gudiol F
    J Antimicrob Chemother; 2005 Oct; 56(4):709-16. PubMed ID: 16120625
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adaptation of methicillin-resistant Staphylococcus aureus in the face of vancomycin therapy.
    Sakoulas G; Moellering RC; Eliopoulos GM
    Clin Infect Dis; 2006 Jan; 42 Suppl 1():S40-50. PubMed ID: 16323119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus.
    Charles PG; Ward PB; Johnson PD; Howden BP; Grayson ML
    Clin Infect Dis; 2004 Feb; 38(3):448-51. PubMed ID: 14727222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Introduction: Solving the clinical problem of vancomycin resistance.
    Moellering RC; Ferraro MJ
    Clin Infect Dis; 2012 Apr; 54 Suppl 3():S201-2. PubMed ID: 22431849
    [No Abstract]   [Full Text] [Related]  

  • 29. Update on emerging infections: news from the Centers for Disease Control and Prevention.
    Moran GJ; Mount J
    Ann Emerg Med; 2003 Jan; 41(1):148-51. PubMed ID: 12514697
    [No Abstract]   [Full Text] [Related]  

  • 30. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Bennett JW; Murray CK; Holmes RL; Patterson JE; Jorgensen JH
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vancomycin resistance in Staphylococcus aureus.
    Appelbaum PC; Bozdogan B
    Clin Lab Med; 2004 Jun; 24(2):381-402. PubMed ID: 15177846
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Method of detecting beta-lactam antibiotic induced vancomycin resistant MRSA (BIVR).
    Hanaki H; Yamaguchi Y; Nomura S; Haraga I; Nagayama A; Sunakawa K
    Int J Antimicrob Agents; 2004 Jan; 23(1):1-5. PubMed ID: 14732306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamic effect of clinical vancomycin exposures on cell wall thickness in heterogeneous vancomycin-intermediate Staphylococcus aureus.
    Rose WE; Knier RM; Hutson PR
    J Antimicrob Chemother; 2010 Oct; 65(10):2149-54. PubMed ID: 20693174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Key considerations in the treatment of complicated staphylococcal infections.
    Jones RN
    Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():3-9. PubMed ID: 18226084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneous vancomycin-resistant Staphylococcus aureus (hetero-VISA) in Singapore.
    Sng LH; Koh TH; Wang GC; Hsu LY; Kapi M; Hiramatsu K
    Int J Antimicrob Agents; 2005 Feb; 25(2):177-9. PubMed ID: 15664490
    [No Abstract]   [Full Text] [Related]  

  • 36. Staphylococcus aureus with reduced susceptibility to vancomycin in a dialysis graft.
    Perla RJ; Knutson EL; Fontana JL
    Clin Infect Dis; 2005 Aug; 41(4):566-7. PubMed ID: 16028171
    [No Abstract]   [Full Text] [Related]  

  • 37. [Infections of vancomycin resistant enterococci (VRE) and Staphylococcus aureus (VRSA)].
    Kuwahara K; Hanaki H; Hiramatsu K
    Ryoikibetsu Shokogun Shirizu; 1999; (23 Pt 1):182-5. PubMed ID: 10088368
    [No Abstract]   [Full Text] [Related]  

  • 38. [Guidelines for antimicrobial treatment of the infection by Staphylococcus aureus].
    Mensa J; Soriano A; Llinares P; Barberán J; Montejo M; Salavert M; Alvarez-Rocha L; Maseda E; Moreno A; Pasquau J; Gómez J; Parra J; Candel F; Azanza JR; García JE; Marco F; Soy D; Grau S; Arias J; Fortún J; de Alarcón CA; Picazo J; ; ;
    Rev Esp Quimioter; 2013 Jan; 26 Suppl 1():1-84. PubMed ID: 23824510
    [No Abstract]   [Full Text] [Related]  

  • 39. Hip arthroplasty infection with heterogeneous vancomycin-resistant Staphylococcus aureus.
    Zeller V; Kitzis MD; Graff W; Mamoudy P; Desplaces N
    Scand J Infect Dis; 2006; 38(10):934-8. PubMed ID: 17008244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation of beta-lactam antibiotic-induced vancomycin-resistant MRSA (BIVR).
    Hanaki H; Yamaguchi Y; Yanagisawa C; Uehara K; Matsui H; Yamaguchi Y; Hososaka Y; Barada K; Sakai F; Itabashi Y; Ikeda S; Atsuda K; Tanaka H; Inamatsu T; Nagayama A; Sunakawa K
    J Infect Chemother; 2005 Apr; 11(2):104-6. PubMed ID: 15856381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.